Skip to main content

Table 4 Activity of fotemustine according to line of chemotherapy and histotype

From: Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation

  Activity in 2nd line
no. pts (%)
(histotype)
Activity in 3rdline
no. pts (%)
(histotype)
Total pts
Partial Response 5 (16.5%)
(1 GBM, 2 AA, 2 AOD)
3 (30%)
(1 AA, 2 AOD)
8
Stable Disease 9 (30%)
(3 GBM, 4 AA, 1 AOA, 1 AOD)
2 (20%)
(1 GBM, 1 AOA)
11
Progression 16 (53.5%)
(7 GBM, 3 AA, 4 AOA, 2 AOD)
5 (50%)
(2 GBM, 1 AA, 1 AOA, 1 AOD)
21
Total pts 30 10 40
  1. AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma, AOD, anaplastic oligodendroglioma; GBM, glioblastoma multiforme; no., number; pts, patients